Rigel is a South San Francisco biotechnology company that develops and sells medicines for blood disorders and cancer. It last closed at $40.09 on Nov 20, down 2.67% on the day. The next earnings report for RIGL is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, RIGL reported EPS of $0.65 on revenue of $80.9M, with revenue up 16.5% from a year ago. Over its last 8 reports the stock moved an average of 11.6% the session after earnings. Over the last 12 months RIGL insiders bought $0 of stock on the open market and sold $306K, according to SEC Form 4 filings.
AI Auto Pilots
Is RIGL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RIGL.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on RIGLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
RIGL · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold
The stock is 15% below its 20 day and 17% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $39.25, and the nearest resistance the Pivot at $40.46.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.9%/day
Key levels
$52.6052 week high+31.2%
$46.9050 day average+17.0%
$46.0520 day average+14.9%
$44.72100 day average+11.5%
$43.34Swing high (Jul 16)+8.1%
$41.29Pivot R1+3.0%
$40.46Pivot+0.9%
$40.09Last close
$39.25Pivot S1−2.1%
$37.76200 day average−5.8%
$37.60Swing low (Nov 6)−6.2%
$24.9552 week low−37.8%
Indicators
RSI (14)
35.07
Weak, oversold below 30
Neutral
MACD
-1.71
Below its signal line
Bearish
Stochastic
25.2
Middle of its range
Neutral
ADX (14)
24.1
Weak trend
Williams %R
-82.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-102.2
Oversold below −100, overbought above 100
Oversold
Rate of change
+1.1%
Change over 10 sessions
Bullish
ATR (14)
$2.35
Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Uptrend
Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 12.5%/day
Key levels
$52.6052 week high+31.2%
$46.9050 day average+17.0%
$46.0520 day average+14.9%
$44.72100 day average+11.5%
$43.34Swing high (Jul 16)+8.1%
$41.29Pivot R1+3.0%
$40.46Pivot+0.9%
$40.09Last close
$39.25Pivot S1−2.1%
$37.76200 day average−5.8%
$37.60Swing low (Nov 6)−6.2%
$24.9552 week low−37.8%
Indicators
RSI (14)
47.45
Middle of its range
Neutral
MACD
2.22
Below its signal line
Bearish
Stochastic
27.4
Middle of its range
Neutral
ADX (14)
27.0
Trending down
Williams %R
-83.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-55.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−15.1%
Change over 10 sessions
Bearish
ATR (14)
$5.02
Typical daily range, 12.5% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for RIGL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RIGL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow RIGL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for RIGLHow many large options trades hit RIGL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in RIGL in the last 90 days.
From SEC Form 4 filings by RIGL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RIGL is in one of them and how their past RIGL trades turned out.
Rigel is a biotechnology company based in South San Francisco, California, that develops and sells medicines for patients with blood disorders and cancer. Its approved products include TAVALISSE, an oral medicine for adults with chronic immune thrombocytopenia, REZLIDHIA for certain adults with relapsed or refractory acute myeloid leukemia, and GAVRETO for certain lung and thyroid cancers. The company is also developing other treatments, including an experimental drug for a blood disorder called myelodysplastic syndrome.